Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 15 mcgHA/Strain/0.5mL) for the Use in the Season 2013/2014 in Adult and Elderly Subjects

Trial Profile

Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 15 mcgHA/Strain/0.5mL) for the Use in the Season 2013/2014 in Adult and Elderly Subjects

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Oct 2015

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 19 Oct 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top